The effectiveness and safety of palbociclib and ribociclib in stage IV HR+/HER-2 negative breast cancer: a nationwide real world comparative retrospective cohort study

Al-Ziftawi, NH; Elazzazy, S; Alam, MF; Shafie, A; Hamad, A; Bbujassoum, S; Ibrahim, MIM

Elazzazy, S (通讯作者)，Hamad Med Corp, Natl Ctr Canc Care & Res, Pharm Dept, Doha, Qatar.

FRONTIERS IN ONCOLOGY, 2023; 13 ():

Abstract

Introduction: Palbociclib and ribociclib are indicated in the first-line treatment of hormonal receptor-positive HER-2 negative (HR+/HER2- negative) a......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索